Analysis of matrix metalloproteinase-9 gene polymorphism -1562 C/T in patients suffering from systemic sclerosis with and without ulcers

International Journal of Molecular Medicine

Volumn 27, Issue 6, 2011, Pages 873-877

  Skarmoutsou, Evangelia ^a   D'Amico, Fabio ^a   Marchini, Maurizio ^b   Stivala, Franca ^a   Malaponte, Grazia ^a   Scorza, Raffaella ^b   Mazzarino, Maria Clorinda ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Matrix metalloproteinase 9; Single nucleotide polymorphism; Systemic sclerosis; Ulcer

Indexed keywords

GELATINASE B;

ADULT; ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENOTYPE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC SCLEROSIS; ULCER;

AGED; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SCLERODERMA, SYSTEMIC; ULCER;

EID: 79954509562     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.661     Document Type: Article

References (41)

1. Silver RM: Clinical aspect of systemic sclerosis (scleroderma). Ann Rheum Dis 50: 854-861, 1991.
2. Allanore Y, Wipff J, Kahan A and Boileau C: Genetic basis for systemic sclerosis. Joint Bone Spine 74: 577-583, 2007.
3. Geyer M and Müller-Ladner U: The pathogenesis of systemic sclerosis revisited. Clin Rev Allergy Immunol: Jan 20, 2010 (Epub ahead of print).
4. Abraham DJ, Krieg T, Distler J and Distler O: Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 48 (Suppl. 3): S3-S7, 2009.
5. Galis ZS and Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90: 251-262, 2002.
6. Ye S: Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 19: 623-629, 2000.
7. Ram M, Sherer Y and Shoenfeld Y: Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 26: 299-307, 2006.
8. Wipff J, Dieude P, Avouac J, et al: Association of metalloproteinase gene polymorphisms with systemic sclerosis in the European Caucasian population. J Rheumatol 37: 599-602, 2010.
9. Zhang B, Ye S, Herrmann SM, et al: Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99: 1788-1794, 1999.
10. Das S, Banerji A, Frei E and Chatterjee A: Rapid expression and activation of MMP-2 and MMP-9 upon exposure of human breast cancer cells (MCF-7) to fibronectin in serum free medium, Life Sci 82: 9-10, 2008.
11. Blankenberg S, Rupprecht HJ, Poirier O, et al: Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107: 1579-1585, 2003.
12. LeRoy EC and Medsger TA Jr: Criteria for the classification of early systemic sclerosis. J Rheumatol 28: 1573-1576, 2001.
13. Denton CP and Korn JH: Digital ulceration and critical digital ischaemia in scleroderma. Scleroderma Care Res 1: 12-16, 2003.
14. Chung L and Fiorentino D: Digital ulcers in patients with systemic sclerosis. Autoimmun Rev 5: 125-128, 2006.
15. Korn JH, Mayes M, Matucci-Cerinic M, et al: Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50: 3985-3993, 2004.
16. Wigley FM: Vascular disease in scleroderma. Clin Rev Allergy Immunol 36: 150-175, 2009.
17. Lenna S, Townsend DM, Tan FK, et al: HLA-B35 upregulates endothelin-1 and downregulates endothelial nitric oxide synthase via endoplasmic reticulum stress response in endothelial cells. J Immunol 184: 4654-4661, 2010.
18. Manabe T, Imoto K, Uchida K, Doi C and Takanashi Y: Decreased tissue inhibitor of metalloproteinase-2/matrix metalloproteinase ratio in the acute phase of aortic dissection. Surg Today 34: 220-225, 2004.
19. Giannelli G, Iannone F, Marinosci F, Lapadula G and Antonaci S: The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. Curr Med Res Opin 21: 327-332, 2005.
20. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23: 581-590, 1980.
21. LeRoy EC, Black C, Fleischmajer R, et al: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15: 202-205, 1988.
22. Johnson RW, Reveille JD, McNearney T, et al: Lack of association of a functionally relevant single nucleotide polymorphism of matrix metalloproteinase-1 promoter with systemic sclerosis (scleroderma). Genes Immun 2: 273-275, 2001.
23. Joung CI, Na YI, Shin ES, Sung YK, Yoo DH and Jun JB: The single nucleotide polymorphisms of matrix metalloproteinase-1 in patients with systemic sclerosis. Rheumatol Int 28: 1183-1185, 2008.
24. Manetti M, Ibba-Manneschi L, Fatini C, et al: Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population. J Rheumatol 37: 1852-1857, 2010.
25. Oliver JE and Silman AJ: Why are women predisposed to autoimmune rheumatic diseases? Arthritis Res Ther 11: 252, 2009.
26. Ozbalkan Z, Bagislar S, Kiraz S, et al: Skewed X-chromosome inactivation in blood cells of women with scleroderma. Arthritis Rheum 52: 1564-1570, 2005.
27. Invernizzi P, Miozzo M, Selmi C, et al: X-chromosome monosomy: a common mechanism for autoimmune diseases. J Immunol 175: 575-578, 2005.
28. Orbach H and Shoenfeld Y: Hyperprolactinemia and autoimmune diseases. Autoimmun Rev 6: 537-542, 2007.
29. Thrailkill KM, Moreau CS, Cockrell GE, et al: Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus. Endocrine 37: 336-343, 2010.
30. Ailawadi G, Eliason JL, Roelofs KJ, et al: Gender differences in experimental aortic aneurysm formation. Arterioscler Thromb Vasc Biol 24: 2116-2122, 2004.
31. Woodrum DT, Ford JW, Ailawadi G, et al: Gender differences in rat aortic smooth muscle cell matrix metalloproteinase-9. J Am Coll Surg 201: 398-404, 2005.
32. Hung KH, Hung HW, Yang HB, Lu CC, Wu JJ and Sheu BS: Host single nucleotide polymorphisms of MMP-9-1562/TIMP-1 372 have gender differences in the risk of gastric intestinal metaplasia after Helicobacter pylori infection. Helicobacter 14: 580-587, 2009.
33. Distler JH, Gay S and Distler O: Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology (Oxford) (Suppl. 3): S26-S27, 2006.
34. Trojanowska M: Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol 8: 453-560, 2010.
35. Arihiro S, Ohtani H, Hiwatashi N, Torii A, Sorsa T and Nagura N: Vascular smooth muscle cells and pericytes express MMP-1, MMP-9, TIMP-1 and type I procollagen in inflammatory bowel disease. Histopathology 39: 50-59, 2001.
36. Hulkkonen J, Pertovaara M, Antonen J, et al: Matrix metalloproteinase 9 (MMP-9) gene polymorphism and MMP-9 plasma levels in primary Sjogren's syndrome. Rheumatology (Oxford) 43: 1476-1479, 2004.
37. Kim WU, Min SY, Cho ML, et al: Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis Res Ther 7: R71-R79, 2005.
38. Kikuchi K, Kubo M, Hoashi Tand Tamaki K: Decreased MMP-9 activity in the serum of patients with diffuse cutaneous systemic sclerosis. Clin Exp Dermatol 27: 301-305, 2002.
39. Folkman J: Endogenous angiogenesis inhibitors. APMIS 112: 496-507, 2004.
40. Martin MD and Matrisian LM: The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 26: 717-724, 2007.
41. Indelicato M, Chiarenza V, Libra M, et al: Analysis of TIMP-1 gene polymorphisms in Italian sclerodermic patients. J Clin Lab Anal 20: 173-176, 2006.